Displaying drugs 12076 - 12100 of 14627 in total
Glycyrrhiza uralensis root
Experimental
Inodiftagene vixteplasmid
Inodiftagene vixteplasmid is a plasmid DNA vector encoding the diphtheria toxin A (dT-a) gene under transcriptional regulation of the promoter region of the human H19 gene (an imprinted maternally expressed non-protein coding gene).
Investigational
Timrepigene emparvovec
Investigational
PEGylated Recombinant Factor VIII
PEGylated Recombinant Factor VIII is under investigation in clinical trial NCT02585960 (BAX 855 Pk-guided Dosing).
Investigational
GP2 peptide
GP2 peptide is under investigation in clinical trial NCT00524277 (Vaccine Therapy in Treating Patients With Breast Cancer).
Investigational
Onfekafusp alfa
Onfekafusp alfa is under investigation in clinical trial NCT02938299 (Neoadjuvant L19IL2/L19TNF- Pivotal Study).
Investigational
Pemlimogene merolisbac
Pemlimogene merolisbac is under investigation in clinical trial NCT03371381 (An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung).
Investigational
Matched Description: … Pemlimogene merolisbac is under investigation in clinical trial NCT03371381 (An Efficacy and Safety Study …
MW33
MW33 is a recombinant fully human antibody to SARS-CoV-2. This antibody injection is currently being investigated against COVID-19 in the clinical trial NCT04533048 (A Clinical Study to Evaluate MW33 Injection).
Investigational
Telazorlimab
Telazorlimab is under investigation in clinical trial NCT03568162 (Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis).
Investigational
Matched Description: … Telazorlimab is under investigation in clinical trial NCT03568162 (Phase 2b Study to Evaluate the Efficacy and …
Tesnatilimab
Tesnatilimab is under investigation in clinical trial NCT04655807 (A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease).
Investigational
Coprelotamab
Coprelotamab is under investigation in clinical trial NCT04170595 (Clinical Study of Recombinant Anti-her2 Humanized Monoclonal Antibody for Injection).
Investigational
Tiragolumab
Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).
Investigational
Matched Description: … Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab …
Datopotamab deruxtecan
Datopotamab deruxtecan is under investigation in clinical trial NCT04656652 (Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)).
Investigational
TMV-083
TMV-083 is an attenuated live virus COVID-19 vaccine candidate which employs the measles vaccine as a vector . It expresses a spike protein antigen from SARS-CoV-2 .
Investigational
V591
The V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles vaccine virus as a vector for COVID-19 antigen delivery . Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and accelerate the development of V591 to phase I...
Investigational
Matched Description: … Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and …
Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)
The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853]. In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection . It...
Investigational
Matched Description: … In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce ... These promising results have secured a Phase I trial (NCT04530656) to evaluate the safety, efficacy, and …
Efzofitimod
Efzofitimod (ATYR1923) is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody. It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states.
Investigational
Matched Description: … It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response …
Zofin
Zofin, previously known as Organicell Flow, is a nanoparticle-based therapeutic derived from perinatal sources which is manufactured in a way that retains the naturally occurring microRNAs without the addition of other substances .
Investigational
COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection
COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection is an intradermal injection currently being investigated in the clinical trial NCT03348670 (Discovery Stage (Proof-of-concept) COVID-19 Antigen Presentation Therapeutic Biologics (COVID-19--AP) (AP-TP-Bio)) .
Investigational
Bacillus clausii
Experimental
Lactobacillus casei
Experimental
Streptococcus thermophilus
Experimental
Lactobacillus paracasei
Experimental
Spermaceti
Experimental
Tosatoxumab
Tosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin[A191829, L31568, L31573] and thereby preserving human immune cells by protecting against destruction of host cells mediated by the toxin.
Investigational
Matched Description: … targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin[A191829, L31568, L31573] and …
Displaying drugs 12076 - 12100 of 14627 in total